DTC
BCAX

Deep Track Capital’s Bicara Therapeutics BCAX Stock Holding History

Deep Track Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.8M Buy
4,062,500
+1,448,496
+55% +$24.9M 1.32% 25
2025
Q4 		$44M Buy
2,614,004
+187,347
+8% +$3.2M 0.78% 33
2025
Q3 		$38.3M Hold
2,426,657
– – 1.07% 30
2025
Q2 		$22.5M Buy
2,426,657
+426,657
+21% +$5.08M 0.72% 36
2025
Q1 		$26.1M Hold
2,000,000
– – 0.84% 31
2024
Q4 		$34.8M Buy
2,000,000
+1,203,148
+151% +$25M 1.3% 26
2024
Q3 		$20.3M Buy
+796,852
New +$20.3M 0.64% 43

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM

Deep Track Capital's BCAX Position: Q1 2026 in Review

Deep Track Capital increased its Bicara Therapeutics (BCAX) stake by 55% in Q1 2026, buying an estimated $24.9M and bringing the position to 4,062,500 shares worth $80.8M. The position accounts for 1.32% of the portfolio, ranked #25.

Deep Track Capital first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Deep Track Capital held 4,062,500 shares of Bicara Therapeutics worth $80.8M as of Q1 2026.
  • Deep Track Capital bought 1,448,496 Bicara Therapeutics shares in Q1 2026, an estimated $24.9M.
  • Bicara Therapeutics made up 1.32% of Deep Track Capital's portfolio in Q1 2026, its #25 holding.
  • Deep Track Capital first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.